Back

Effect on Oxidized Phospholipids of Lepodisiran, an Extended Duration siRNA Targeting Lipoprotein(a)

31 August 2026 (09:30 - 09:45)
Organised by: Logo
Congress Presentation Part of: Beyond statins: the next wave of lipid-lowering therapies Drug therapy ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Steven E Nissen

Cleveland Clinic Hospital, Cleveland (United States of America)

5 More presentations in this session

Presentation thumbnail
Head-to-head comparison of inclisiran vs bempedoic acid for LDL C lowering in patients with high and very high cardiovascular risk: Results from the phase 4 VICTORION-CHALLENGE trial
Professor I. Hilgendorf (Berlin, DE)
Slides Video
Presentation thumbnail
Oral HRS-5346, a novel small molecule lipoprotein(a) inhibitor, in adults at high cardiovascular risk with elevated lipoprotein(a): a phase 2, randomized, double-blind study
Doctor D. Zhu (Beijing, CN)
Slides Video
Presentation thumbnail
Protocol-based early intensive lipid management in patients with acute coronary syndrome (BRIDGE): A multicenter prospective cluster-randomized controlled trial
Doctor K. Oyama (Sendai, JP)
Slides Video
Presentation thumbnail
A phase 3 clinical trial to evaluate the efficacy and safety of vsa003 injection in chinese adolescents and adults with homozygous familial hypercholesterolaemia (hofh)
Doctor Z. Tian (Beijing, CN)
Slides Video
Presentation thumbnail
Effects of Evolocumab on Fatal Outcomes in Patients Without a Prior Myocardial Infarction or Stroke : Pre-specified Analysis of the VESALIUS-CV Trial
Doctor R. Giugliano (Boston, US)
Slides Video

Access the full session

Session thumbnail
Beyond statins: the next wave of lipid-lowering therapies
Video

The Event

Event poster

ESC Congress 2026

31 August 2026 09:30 CET
You may be interested in
thumbnail
Congress Presentation
siRNAs to lower Lp(a)
28 August 2026
thumbnail
Congress Presentation
The future of lipid management: novel therapeutics and the path forward
31 August 2025
thumbnail
Congress Presentation
Proteomic signatures reveal why not all apolipoprotein B-containing lipoproteins are equal in atherosclerosis
31 August 2026
thumbnail
Congress Presentation
Efficacy and safety of SYH2053 in patients with primary hypercholesterolemia or mixed dyslipidemia: a phase II, multicenter, randomized, double-blind, placebo- and active-controlled trial
31 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources